Ropinirole is a non-ergot dopamine agonist used for the treatment of Parkinson's disease and Restless Legs Syndrome (RLS). It provides dopaminergic stimulation by selectively binding to D2 and D3 receptors with minimal activity at other receptor subtypes. [1]
| Property | Value | [2]
|----------|-------| [3]
| Drug Class | Dopamine Agonist | [4]
| Approval Status | FDA Approved (1998) | [5]
| Brand Names | Requip, Requip XL, Ropinirole Hydrochloride | [6]
| Mechanism | D2/D3 receptor agonist | [7]
| Route of Administration | Oral (immediate and extended-release) | [8]
| Half-life | 6 hours |
Ropinirole exerts its therapeutic effects through:
| Parameter | Value |
|---|---|
| Bioavailability | ~50% |
| Protein Binding | ~10-40% |
| Metabolism | Hepatic (CYP1A2, CYP3A4) |
| Elimination | Renal (~90%) |
| Time to Peak | 1-2 hours |
| Interacting Drug | Effect |
|---|---|
| Ciprofloxacin | Increased ropinirole levels |
| Estrogens | May increase levels |
| Antipsychotics | May reduce dopamine agonist effect |
| Metoclopramide | Antagonistic effect |
The study of Ropinirole Dopamine Agonist For Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Adler CH, et al. "Ropinirole for the treatment of early Parkinson's disease." Neurology. Neurology. 1997. ↩︎
Brooks DJ, et al. "Ropinirole in the symptomatic treatment of Parkinson's disease." J Neurol Neurosurg Psychiatry. J Neurol Neurosurg Psychiatry. 2000. ↩︎
Pahwa R, et al. "Ropinirole hydrochloride for the treatment of Restless Legs Syndrome." Expert Opin Pharmacother. Expert Opin Pharmacother. 2006. ↩︎
Hauser RA, et al. "Long-term outcome of ropinirole treatment in Parkinson disease." Clin Neuropharmacol. Clin Neuropharmacol. 2006. ↩︎
Antonini A, et al. "Ropinirole for the treatment of Parkinson's disease." Expert Opin Drug Metab Toxicol. Expert Opin Drug Metab Toxicol. 2010. ↩︎
Kurlan R. "Ropinirole for Restless Legs Syndrome." N Engl J Med. N Engl J Med. 2005. ↩︎
Stowe R, et al. "Ropinirole for the treatment of Parkinson's disease." Cochrane Database Syst Rev. Cochrane Database Syst Rev. 2008. ↩︎
Trenkwalder C, et al. "Efficacy of ropinirole in Restless Legs Syndrome." Mov Disord. Mov Disord. 2004. ↩︎